Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Annals of Nuclear Medicine Pub Date : 2023-10-20 DOI:10.1007/s12149-023-01873-6

Yuji Nakamoto, Shingo Baba, Hayato Kaida, Osamu Manabe, Tomoya Uehara

{"title":"Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects","authors":"Yuji Nakamoto, Shingo Baba, Hayato Kaida, Osamu Manabe, Tomoya Uehara","doi":"10.1007/s12149-023-01873-6","DOIUrl":null,"url":null,"abstract":"<div><p>Recently, positron emission tomography (PET) with fibroblast activation protein inhibitor (FAPI) has gained significant attention as an advanced tumor diagnostic imaging tool. FAPI PET has a promising potential owing to its ability to accurately depict most malignant tumors. It has an accuracy that is comparable to or surpassing the diagnostic accuracy of PET using <sup>18</sup>F-fluorodeoxyglucose (FDG). Moreover, FAPI PET can identify malignant lesions that may be inconclusive on FDG PET. Beyond its application in neoplastic disorders, there have been encouraging reports suggesting the utility of FAPI PET in non-neoplastic conditions such as respiratory or cardiac diseases. This article aimed to provide a comprehensive overview of the recently published articles investigating FAPI and discuss its clinical utility with an emphasis on its application in tumor diagnostics. Numerous radiopharmaceutical FAPIs, including <sup>18</sup>F- and <sup>68</sup>Ga-labeled compounds, have been developed, and they offer various advantages and applications. With the progress in the FAPI PET synthesis to enhance accumulation and retention in pathological lesions, future studies are expected to provide valuable data on its therapeutic efficacy.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-023-01873-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Recently, positron emission tomography (PET) with fibroblast activation protein inhibitor (FAPI) has gained significant attention as an advanced tumor diagnostic imaging tool. FAPI PET has a promising potential owing to its ability to accurately depict most malignant tumors. It has an accuracy that is comparable to or surpassing the diagnostic accuracy of PET using ¹⁸F-fluorodeoxyglucose (FDG). Moreover, FAPI PET can identify malignant lesions that may be inconclusive on FDG PET. Beyond its application in neoplastic disorders, there have been encouraging reports suggesting the utility of FAPI PET in non-neoplastic conditions such as respiratory or cardiac diseases. This article aimed to provide a comprehensive overview of the recently published articles investigating FAPI and discuss its clinical utility with an emphasis on its application in tumor diagnostics. Numerous radiopharmaceutical FAPIs, including ¹⁸F- and ⁶⁸Ga-labeled compounds, have been developed, and they offer various advantages and applications. With the progress in the FAPI PET synthesis to enhance accumulation and retention in pathological lesions, future studies are expected to provide valuable data on its therapeutic efficacy.

Abstract Image

查看原文本刊更多论文

成纤维细胞活化蛋白抑制剂PET/CT的最新主题：临床和药理学方面。

近年来，含有成纤维细胞活化蛋白抑制剂（FAPI）的正电子发射断层扫描（PET）作为一种先进的肿瘤诊断成像工具受到了极大的关注。FAPIPET由于其能够准确描述大多数恶性肿瘤而具有很有前途的潜力。其准确度与使用18F-氟脱氧葡萄糖（FDG）的PET的诊断准确度相当或超过PET的诊断准确性。此外，FAPI PET可以识别FDG PET上可能没有结论的恶性病变。除了在肿瘤性疾病中的应用外，还有令人鼓舞的报告表明FAPI-PET在非肿瘤性疾病（如呼吸或心脏疾病）中的应用。本文旨在全面综述最近发表的研究FAPI的文章，并讨论其临床应用，重点是其在肿瘤诊断中的应用。已经开发了许多放射性药物FAPI，包括18F-和68Ga标记的化合物，它们提供了各种优点和应用。随着FAPI PET合成在增强病理病变中的积聚和滞留方面的进展，未来的研究有望为其治疗效果提供有价值的数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Nuclear Medicine 医学-核医学

CiteScore

4.90

自引率

7.70%

发文量

111

审稿时长

4-8 weeks

期刊介绍： Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.